查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1944421

全球眼科药品市场按剂型、治疗领域、应用、给药途径、国家及地区划分－产业分析、市场规模、市占率及2025-2032年预测

Ophthalmic Drugs Market, By Formulation Type, By Therapeutic Area, By Application, By Route of Administration, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 321 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2024年眼科药品市场规模价值404.5634亿美元，从2025年到2032年将以8.45%的复合年增长率成长。

眼科药物是专门用于识别、治疗、预防和管理影响眼部及周围组织的眼科疾病的医疗产品。专家提供眼药水、眼膏、凝胶、植体和注射等局部治疗方案，确保药物精准输送，同时最大限度地减少全身不良反应。眼科药物可用于治疗多种眼部疾病，包括青光眼、干眼症、结膜炎、葡萄膜炎、老龄化黄斑部病变、糖尿病视网膜病变、眼部感染疾病和眼部发炎。产品包含的活性成分包括抗生素、抗发炎药、青光眼药物、抗病毒药、抗霉菌药和生物製药。由于眼部组织需要特殊保护，研究人员制定了严格的无菌和安全标准。

眼科药品市场 - 市场动态

眼科疾病呈上升趋势

随着全球眼科疾病发生率的上升，眼科药品市场也不断扩张。包括青光眼、白内障、老龄化黄斑部病变、糖尿病视网膜病变、干眼症和感染性结膜炎在内的各种眼疾发生率持续攀升，对有效眼科治疗的需求也随之增加。全球眼科疾病率的上升是由多种因素造成的，包括人口老化、糖尿病盛行率上升、萤幕使用时间增加、都市化进程加快、环境污染。患者对早期诊断、长期治疗和疾病管理的需求，推动了处方笺和非处方药的需求成长，从而带动了已开发市场和新兴市场眼科药品市场的持续成长。

例如，根据世界卫生组织（世卫组织）的数据，全球至少有 22 亿人因近视或远视而视力受损，其中 1 亿例是可以预防的，但仍未解决。

眼科药品市场－细分市场分析：

透过使用

2024年，抗发炎药物占了相当大的收入份额。医生使用包括皮质类固醇和非类固醇消炎剂眼科药物来治疗多种眼科疾病。由于全球人口老化导致眼科疾病增加、眼科手术量增加以及慢性眼科疾病率上升，对这些治疗方法的需求不断增加。製剂技术的进步，例如无防腐剂眼药水和缓释给药系统，提高了抗发炎药物的疗效、安全性和患者依从性，从而促进了医生和患者的使用。临床和技术进步的共同推动了眼科药品市场中抗发炎药物类别的收入成长。

透过行政途径

局部用药占市场主导地位。临床医生更倾向于使用局部眼科药物，因为这些药物可以直接作用于眼表，并即时缓解症状。局部治疗在治疗干眼症、过敏性结膜炎和局部发炎等常见眼科疾病疗效显着，加之新型无防腐剂溶液和改良给药系统的出现，提高了患者的舒适度和治疗依从主导，因此该局部市场一直保持着收入领先地位。这些因素共同推动了局部眼科药物市场的持续成长。

眼科药品市场－区域分析

在预测期内，北美将占据最大的收入份额。这一高份额主要归因于两个因素：视网膜疾病发生率的上升以及该地区政府的优惠政策。北美是一个已开发地区，医疗保健支出庞大。北美市场扩张的原因有两个：一是需要眼科护理的人数不断增加，二是眼科手术数量的增加。美国和加拿大需求的成长主要源自于老年人口的成长，因为老年人比年轻人更容易需要眼科照护。此外，该地区糖尿病患者数量的增加也导致了用于治疗糖尿病眼科疾病的眼科药物需求的增加。

目录

第一章 眼科药品市场概览

  • 调查范围
  • 市场预测期

第二章执行摘要

  • 市场区隔
  • 竞争考察

第三章：眼科药品市场：主要市场趋势

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 未来市场趋势

第四章 眼科药物治疗领域研究

  • PEST分析
  • 波特五力分析
  • 成长前景分析
  • 法规结构分析

第五章 眼科药品市场：地缘政治紧张局势加剧的影响

  • 新冠疫情的影响
  • 俄乌战争的影响
  • 中东衝突的影响

第六章 眼科药品市场概况

  • 眼科药品市占率分析（2024 年）
  • 主要製造商的细分数据
    • 对现有公司的分析
    • 新兴企业分析

7. 按剂型分類的眼科药品市场

  • 概述
    • 细分市场占有率分析：依配方类型
    • 注射
    • 凝胶
    • 软膏
    • 眼药水
    • 缓释製剂

8. 眼科药品市场依治疗领域划分

  • 概述
    • 细分市场占有率分析：依治疗领域划分
    • 视网膜疾病
    • 白内障手术
    • 过敏性结膜炎
    • 感染疾病
    • 眼压升高

第九章 眼科药品市场（依应用领域划分）

  • 概述
    • 细分市场占有率分析：按应用
    • 抗病毒物质
    • 抗生素
    • 消炎（药）
    • 青光眼
    • 干眼症

第十章 依给药途径分類的眼科药品市场

  • 概述
    • 细分市场占有率分析：依管理途径
    • 局部的
    • 结膜下
    • 玻璃体内注射
    • 全身给药
    • 眼周

第十一章 眼科药品市场（按地区划分）

  • 介绍
  • 北美洲
    • 概述
    • 北美主要製造商
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲主要製造商
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 瑞典
    • 俄罗斯
    • 波兰
    • 其他的
  • 亚太地区
    • 概述
    • 亚太地区主要製造商
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 菲律宾
    • 其他的
  • 拉丁美洲
    • 概述
    • 拉丁美洲主要製造商
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 其他的
  • 中东和非洲（MEA）
    • 概述
    • 中东和非洲的主要製造商
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • 其他的

第十二章 主要供应商分析－眼科药品

  • 竞争对手仪錶板
    • 竞争基准
    • 竞争定位
  • 公司简介
    • Roche（Genentech, Inc.）
    • Regeneron Pharmaceuticals, Inc.
    • Bausch Health Companies, Inc.
    • Merck &Co., Inc.
    • Novartis AG
    • Coherus BioSciences, Inc.
    • AbbVie, Inc.（Allergan）
    • Pfizer, Inc.
    • Bayer AG
    • Santen Pharmaceutical Co., Ltd.
    • Alcon
    • Nicox

第十三章：分析师视角

简介目录
Product Code: ANV6055

The Ophthalmic Drugs Market size was valued at US$40,456.34 Million in 2024, expanding at a CAGR of 8.45% from 2025 to 2032.

Ophthalmic drugs function as dedicated medical products which enable doctors to identify and treat, prevent, and control eye diseases that affect both the eye and its adjacent tissues. The drugs provide localized treatment through eye drops, ointments, gels, inserts, and ointment and gel and insert and injection methods which specialists use to achieve precise medicine delivery while reducing unwanted effects throughout the body. Ophthalmic drugs provide treatment options for various medical conditions, which include glaucoma, dry eye disease, conjunctivitis, uveitis, age-related macular degeneration, diabetic retinopathy, eye infections, and eye inflammation. The products include active pharmaceutical components which consist of antibiotics and anti-inflammatory drugs, anti-glaucoma medications, antiviral medicines, antifungal agents, and biologic products. Researchers establish strict sterility and safety standards because ocular tissues require special protection.

Ophthalmic Drugs Market- Market Dynamics

Rising prevalence of eye disease

The ophthalmic drugs market is expanding because of the rising number of eye diseases that occur throughout the world. The demand for effective eye treatments remains constant because glaucoma cataracts, age-related macular degeneration, diabetic retinopathy, dry eye disease, and infectious conjunctivitis all show increasing occurrence rates. The worldwide increase of eye disorders results from multiple factors which include population aging and growing diabetes rates, extended screen time, urban living, and environmental pollution. The demand for both prescription and over-the-counter ophthalmic drugs increases as patients need both early diagnosis and extended treatment and disease management which results in continuous market growth for developed nations and emerging markets.

For instance, according to the World Health Organization, globally, at least 2.2 billion people have a near or distance vision impairment.1 billion of these cases involve vision impairment which should have been prevented but remains unresolved.

Ophthalmic Drugs Market- Segmentation Analysis:

By Application

In 2024, the anti-inflammatories held a high revenue share. Doctors use anti-inflammatory ophthalmic drugs which include corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs), to treat multiple eye conditions. The worldwide rise in eye diseases because of population aging, increased eye surgeries, and growing chronic eye disease rates has created a higher demand for these treatments. The development of formulation technologies which include preservative-free eye drops and sustained-release delivery systems, has enhanced anti-inflammatory treatment effectiveness, safety, and patient compliance which doctors and patients now use more frequently. The combination of clinical and technological developments leads to increased revenue growth for the anti-inflammatory category of the ophthalmic drugs market.

By Route of Administration

The topical dominates the market. Doctors prefer topical ophthalmic drugs in clinical settings because these medications enable direct eye surface delivery and provide immediate symptom relief. The segment maintains its revenue leadership because topical treatments show high success rates for managing common eye diseases like dry eye and allergic conjunctivitis and postoperative inflammation and new topical formulations with preservative-free solutions and improved delivery systems increase patient comfort and treatment compliance. The ophthalmic drugs market for topical administration methods keeps growing because of these factors.

Ophthalmic Drugs Market- Geographical Insights

North America holds the largest revenue share over the projected period. The high share results from two factors which include the growing occurrence of retinal diseases and the beneficial government programs in the area. North America represents a developed area that spends substantial amounts on healthcare. The North American market expands because of two factors which include the rising number of people who need eye care and the increasing number of eye treatment procedures. The rising demand in the United States and Canada results from the increasing senior population because older people need eye care more than younger people do. The increasing rate of diabetes in the area has created a higher need for ophthalmic drugs that treat diabetic eye conditions.

Ophthalmic Drugs Market- Competitive Landscape:

The ophthalmic drugs market's competitive environment is shaped by various factors, which include large diversified pharmaceutical companies, specialized vision-care businesses, and rapidly developing biologics markets, especially anti-VEGF treatments, ongoing mergers and acquisitions, licensing activities, and increasing competition from generic drugs and biosimilar products. The global leaders in the industry, who include AbbVie (Allergan), Alcon, Bausch + Lomb and Regeneron (with Bayer for Eylea), Novartis, Roche, and Bayer and Santen, sustain their strong market presence through their extensive product offerings and established distribution networks, and their comprehensive research and development programs, which include both small-molecule and biologic ophthalmic treatments.

Recent Developments:

In October 2025, Santen Pharmaceutical Co., Ltd. announced that it launched SETANEO(R) Ophthalmic Solution 0.002% (generic name: sepetaprost; hereafter the product) in Japan, for the treatment of glaucoma and ocular hypertension. The product contains 0.002% sepetaprost, which is a bicyclic prostaglandin derivative that binds to FP and EP3 receptors to increase aqueous humor outflow and decrease intraocular pressure. Santen submitted a manufacturing and marketing authorization application in September 2024 based on Phase III clinical trial results which were conducted in Japan and received approval in August 2025 for glaucoma and ocular hypertension treatment.

In December 2025, Amneal Pharmaceuticals, Inc. declared that the U.S. Food and Drug Administration (FDA) had given its approval to the Company's cyclosporine ophthalmic emulsion 0.05% product which comes as a sterile formulation without preservatives in single-use vials. The product is the generic equivalent of RESTASIS(R) (cyclosporine ophthalmic emulsion) 0.05%, a registered trademark of Allergan, an AbbVie company.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL OPHTHALMIC DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Roche (Genentech, Inc.)
  • Regeneron Pharmaceuticals, Inc.
  • Bausch Health Companies, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Coherus BioSciences, Inc.
  • AbbVie, Inc. (Allergan)
  • Pfizer, Inc.
  • Bayer AG
  • Santen Pharmaceutical Co., Ltd.
  • Alcon
  • Nicox

GLOBAL OPHTHALMIC DRUGS MARKET, BY FORMULATION TYPE- MARKET ANALYSIS, 2019 - 2032

  • Injectables
  • Gels
  • Ointments
  • Eye Drops
  • Sustained Release

GLOBAL OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2019 - 2032

  • Retinal Disorders
  • Cataract Surgery
  • Allergic Conjunctivitis
  • Infectious Diseases
  • Ocular Hypertension

GLOBAL OPHTHALMIC DRUGS MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Antiviral
  • Antibiotic
  • Anti-Inflammatory
  • Glaucoma
  • Dry Eye
  • GLOBAL OPHTHALMIC DRUGS MARKET, ROUTE OF ADMINISTRATION - MARKET ANALYSIS, 2019 - 2032
  • Topical
  • Subconjunctival
  • Intravitreal
  • Systemic
  • Periocular

GLOBAL OPHTHALMIC DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Ophthalmic Drugs Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Ophthalmic Drugs Market Snippet by Formulation Type
    • 2.1.2. Ophthalmic Drugs Market Snippet by Therapeutic Area
    • 2.1.3. Ophthalmic Drugs Market Snippet by Application
    • 2.1.4. Ophthalmic Drugs Market Snippet by Route of Administration
    • 2.1.5. Ophthalmic Drugs Market Snippet by Country
    • 2.1.6. Ophthalmic Drugs Market Snippet by Region
  • 2.2. Competitive Insights

3. Ophthalmic Drugs Key Market Trends

  • 3.1. Ophthalmic Drugs Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Ophthalmic Drugs Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Ophthalmic Drugs Market Opportunities
  • 3.4. Ophthalmic Drugs Market Future Trends

4. Ophthalmic Drugs Therapeutic Area Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Ophthalmic Drugs Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Ophthalmic Drugs Market Landscape

  • 6.1. Ophthalmic Drugs Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Ophthalmic Drugs Market - By Formulation Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Formulation Type, 2024&2032 (%)
    • 7.1.2. Injectables
    • 7.1.3. Gels
    • 7.1.4. Ointments
    • 7.1.5. Eye Drops
    • 7.1.6. Sustained Release

8. Ophthalmic Drugs Market - By Therapeutic Area

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Therapeutic Area, 2024&2032 (%)
    • 8.1.2. Retinal Disorders
    • 8.1.3. Cataract Surgery
    • 8.1.4. Allergic Conjunctivitis
    • 8.1.5. Infectious Diseases
    • 8.1.6. Ocular Hypertension

9. Ophthalmic Drugs Market - By Application

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Application, 2024&2032 (%)
    • 9.1.2. Antiviral
    • 9.1.3. Antibiotic
    • 9.1.4. Anti-Inflammatory
    • 9.1.5. Glaucoma
    • 9.1.6. Dry Eye

10. Ophthalmic Drugs Market - By Route of Administration

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Route of Administration, 2024&2032 (%)
    • 10.1.2. Topical
    • 10.1.3. Subconjunctival
    • 10.1.4. Intravitreal
    • 10.1.5. Systemic
    • 10.1.6. Periocular

11. Ophthalmic Drugs Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024&2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Billion)
    • 11.2.4. North America Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
    • 11.2.5. North America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
    • 11.2.6. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
    • 11.2.7. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.2.8.3. U.S. Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.2.8.4. U.S. Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.2.8.5. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.2.8.6. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.2.9.3. Canada Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.2.9.4. Canada Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.2.9.5. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.2.9.6. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Ophthalmic Drugs Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Billion)
    • 11.3.4. Europe Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
    • 11.3.5. Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
    • 11.3.6. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
    • 11.3.7. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.3.8.3. Germany Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.3.8.4. Germany Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.3.8.5. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.3.8.6. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.3.9.3. UK Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.3.9.4. UK Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.3.9.5. UK Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.3.9.6. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.3.10.3. France Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.3.10.4. France Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.3.10.5. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.3.10.6. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.3.11.3. Italy Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.3.11.4. Italy Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.3.11.5. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.3.11.6. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.3.12.3. Spain Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.3.12.4. Spain Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.3.12.5. Spain Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.3.12.6. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.3.13.6. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.3.14.3. Sweden Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.3.14.4. Sweden Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.3.14.5. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.3.14.6. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.3.15.3. Russia Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.3.15.4. Russia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.3.15.5. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.3.15.6. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.3.16.3. Poland Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.3.16.4. Poland Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.3.16.5. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.3.16.6. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Ophthalmic Drugs Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Billion)
    • 11.4.4. APAC Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
    • 11.4.5. APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
    • 11.4.6. APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
    • 11.4.7. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.4.8.3. China Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.4.8.4. China Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.4.8.5. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.4.8.6. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.4.9.3. India Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.4.9.4. India Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.4.9.5. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.4.9.6. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.4.10.3. Japan Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.4.10.4. Japan Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.4.10.5. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.4.10.6. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.4.11.3. South Korea Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.4.11.4. South Korea Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.4.11.5. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.4.11.6. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.4.12.3. Australia Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.4.12.4. Australia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.4.12.5. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.4.12.6. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.4.13.6. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.4.14.3. Thailand Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.4.14.4. Thailand Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.4.14.5. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.4.14.6. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.4.15.3. PhilippinesMarket Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.4.15.4. Philippines Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.4.15.5. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.4.15.6. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Ophthalmic Drugs Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Billion)
    • 11.5.4. LATAM Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
    • 11.5.5. LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
    • 11.5.6. LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
    • 11.5.7. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.5.8.3. Brazil Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.5.8.4. Brazil Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.5.8.5. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.5.8.6. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.5.9.3. Mexico Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.5.9.4. Mexico Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.5.9.5. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.5.9.6. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.5.10.3. Argentina Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.5.10.4. Argentina Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.5.10.5. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.5.10.6. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.5.11.3. Colombia Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.5.11.4. Colombia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.5.11.5. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.5.11.6. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Ophthalmic Drugs Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Billion)
    • 11.6.4. MEA Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
    • 11.6.5. MEA Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
    • 11.6.6. MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
    • 11.6.7. MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.6.9. UAE
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.6.9.3. UAE Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.6.9.4. UAE Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.6.9.5. UAE Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.6.9.6. UAE Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.6.10.3. Israel Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.6.10.4. Israel Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.6.10.5. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.6.10.6. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.6.11.3. Turkey Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.6.11.4. Turkey Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.6.11.5. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.6.11.6. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.6.12.3. Algeria Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.6.12.4. Algeria Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.6.12.5. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.6.12.6. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.6.13.3. Egypt Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.6.13.4. Egypt Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.6.13.5. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.6.13.6. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)

12. Key Vendor Analysis- Ophthalmic Drugs

  • 12.1. Competitive Dashboard
    • 12.1.1. Competitive Benchmarking
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. Roche (Genentech, Inc.)
    • 12.2.2. Regeneron Pharmaceuticals, Inc.
    • 12.2.3. Bausch Health Companies, Inc.
    • 12.2.4. Merck & Co., Inc.
    • 12.2.5. Novartis AG
    • 12.2.6. Coherus BioSciences, Inc.
    • 12.2.7. AbbVie, Inc. (Allergan)
    • 12.2.8. Pfizer, Inc.
    • 12.2.9. Bayer AG
    • 12.2.10. Santen Pharmaceutical Co., Ltd.
    • 12.2.11. Alcon
    • 12.2.12. Nicox

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us